Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization

Cellular and Molecular Immunology

Volumn 8, Issue 6, 2011, Pages 496-501

  Zhang, Hui ^a   Liu, Liu ^a   Wen, Ke ^a   Huang, Jinlin ^a   Geng, Shizhong ^a   Shen, Junsong ^a   Pan, Zhiming ^a   Jiao, Xinan ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

cellular immune response; ESAT 6; flagellin; intranasal immunization; Mycobacterium tuberculosis

Indexed keywords

BACTERIAL VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; FLAGELLIN; GAMMA INTERFERON; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN DETECTION; ARTICLE; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MEMORY T LYMPHOCYTE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PEYER PATCH; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; SPLEEN; TH1 CELL; TH2 CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; FLAGELLIN; FLUORESCEINS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNIZATION; LYMPH NODES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PEYER'S PATCHES; RECOMBINANT FUSION PROTEINS; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

ANIMALIA; MUS; MYCOBACTERIUM TUBERCULOSIS; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 80755181111     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.24     Document Type: Article

References (34)

1. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 12: 186-191.
2. Martin C. Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 2006, 1997; 49: 7-15.
3. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 2005; 26: 660-667. (Pubitemid 41628199)
4. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254. (Pubitemid 23344886)
5. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12013-12017. (Pubitemid 23004775)
6. 1, T cells in lungs following aerosol infection with Mycobacterium tuberculosis. Infect Immun 1999; 67: 3242-3247. (Pubitemid 29291487)
7. Ladel CH, Blum C, Dreher A, Reifenberg K, Kaufmann SH. Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur J Immunol 1995; 25: 2877-2881.
8. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004; 173: 6357-6365. (Pubitemid 39487795)
9. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 2005; 174: 7986-7994. (Pubitemid 40806309)
10. Carpenter ZK, Williamson ED, Eyles JE. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release 2005; 104: 67-77. (Pubitemid 40615236)
11. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002; 20: 2772-2780. (Pubitemid 34597137)
12. 1 T cells in vivo. J Immunol 2002; 169: 3914-3919.
13. 1 T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 2010; 28: 1373-1382.
14. Hayat MA, Miller SE. Laboratory for advanced electron and light optical methods. Negative Staining. New York: McGraw-Hill Publishing Co.1990:216
15. Lbrahim GF, Fleet GH, Lyons MJ, Walker RA. Method for the isolation of highly purified Salmonella flagellins. J Clin Microbiol 1985; 22: 1040-1044. (Pubitemid 16222735)
16. Sambrook J, Russell DW, Molecular Cloning:A Laboratory Manual.3rd ed New York: Cold Spring Harbor Laboratory Press 2001.
17. Zhang H, Wen K, Shen J, Geng S, Huang J, Pan Z et al. Characterization of immune responses following intranasal immunization with the Mycobacterium bovis CFP-10 protein expressed by attenuated Salmonella typhimurium. Scand J Immunol 2010; 72: 277-283.
18. Reed S, Lobet Y. Tuberculosis vaccine development: from mouse to man. Microbes Infect 2005; 7: 922-931. (Pubitemid 40826661)
19. Skountzou I, Martin M, Wang B, Ye L, Koutsonanos D, Weldon W et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2009; 28: 4103-4112.
20. Verma NK, Ziegler HK, Stocker BA, Schoolnik GK. Induction of a cellular immune response to a defined T-cell epitope as an insert in the flagellin of a live vaccine strain of Salmonella. Vaccine 1995; 13: 235-244.
21. Newton SMC, Joys TM, Anderson SA, Kennedy RC, Hovi ME, Stocker BA. Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol 1995; 146: 203-216.
22. Chauhan N, Kumar R, Badhai J, Preet A, Yadava PK. Immunogenitity of cholera toxin B epitope inserted in Salmonella flagellin expressed on bacteria and administered as DNA vaccine. Mol Cell Biochem 2005; 276: 1-6. (Pubitemid 41236202)
23. Newton SMC, Jacob OC, Stocker BAD. Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science 1989; 244: 70-72. (Pubitemid 19130745)
24. Okazaki N, Matsuo S, Saito K, Tominaga A, Enomoto M. Conversion of the Salmonella phase 1 flagellin gene fliC to the phase 2 gene fljB on the Escherichia coli K-12 chromosome. J Bacteriol 1993; 175: 758-766. (Pubitemid 23046939)
25. Le-Moigne V, Robreau G, Mahana W. Flagellin as a good carrier and potent adjuvant for Th1 responses: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol Immunol 2008; 45: 2499-2507.
26. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23: 5599-5617. (Pubitemid 41608610)
27. McEwen J, Levi R, Horwitz RJ, Arnon R. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 1992; 10: 405-411.
28. Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO. Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 1998; 16: 698-707. (Pubitemid 28172535)
29. Eyles JE, Spiers ID, Williamson ED, Alpa HO. Analysis of local and systemic immunological responses after intra-tracheal, intranasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine 1998; 16: 2000-2009. (Pubitemid 28473949)
30. Garmory HS, Griffin F, Brown KA, Titball RW. Oral immunization with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine 2003; 21: 3051-3057. (Pubitemid 36703213)
31. Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog 1997; 23: 167-179. (Pubitemid 27387534)
32. Morton M, Garmory HS, Perkins SD, O'Dowd AM, Griffin KF, Turner AK et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine 2004; 22: 2524-2532. (Pubitemid 38757355)
33. Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, Mamroud E et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun 2003; 71: 374-383. (Pubitemid 36026041)
34. Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 2004; 22: 3348-3357. (Pubitemid 39078752)